CNSPHealthcare · BiotechnologyCNSP Stock Forecast: CNS Pharmaceuticals, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering CNS Pharmaceuticals, Inc. hold a median 12-month price target of $10 — +72.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
CNSP stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores CNS Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (93): Smaller than most of the companies we track.
Volatility (4): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own CNS Pharmaceuticals, Inc. — and when they’d sell — is the membership.
CNSP stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CNSP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +72.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Sept 2025 | Maxim Group | Upgrade | Buy | $20 |
| 25 Mar 2025 | Maxim Group | Downgrade | Hold | — |
| 10 Sept 2024 | Maxim Group | Upgrade | Buy | $0.50 |
| 2 Feb 2021 | Brookline Capital | Initiates | Buy | $10 |
| 24 Aug 2020 | Ladenburg Thalmann | Initiates | Buy | — |
| 4 Dec 2019 | Benchmark | Initiates | Speculative Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CNSP analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
CNS Pharmaceuticals, Inc. (CNSP) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.0×
- Price / sales
- —
- Price / book
- 66.9×
- EV / EBITDA
- −0.3×
Cheaper than 74% of US stocks
Cheaper than 2% of US stocks
Cheaper than 64% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −298.6%
- Return on assets
- −112.9%
- Dividend yield
- —
Higher than 5% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
CNSP vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CNSP appears on the weeks it earns a place.
Frequently asked questions about CNSP stock
What is the CNSP stock price forecast for 2026-2027?
The 1 Wall Street analysts covering CNS Pharmaceuticals, Inc. have a median 12-month price target of $10, with estimates ranging from $10 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CNSP stock a buy right now?
Of the 1 analysts covering CNS Pharmaceuticals, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CNS Pharmaceuticals, Inc. 37 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CNSP?
As at 1 Aug 2026, CNS Pharmaceuticals, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).
Will CNSP stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +72.7% from the last close, and Ticker Nerd's factor model ranks CNS Pharmaceuticals, Inc. 37 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CNSP stock forecast for 2030?
No analyst covering CNS Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CNSP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $10 over the next 12 months.
How has CNSP stock performed over the past year?
CNS Pharmaceuticals, Inc. returned -24.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does CNS Pharmaceuticals, Inc. do?
CNS Pharmaceuticals Inc. is a preclinical stage biotechnology company dedicated to developing innovative anticancer drug candidates for treating primary and metastatic brain and central nervous system tumors.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals Inc. is a preclinical stage biotechnology company dedicated to developing innovative anticancer drug candidates for treating primary and metastatic brain and central nervous system tumors. The company's primary focus is on glioblastoma multiforme, an aggressive and currently incurable form of brain cancer, along with other gliomas. CNS Pharmaceuticals maintains a specialized product pipeline including berubicin and CNS-12, targeting serious diseases in neurology and oncology. Founded in 2017 and headquartered in Houston, Texas, the company engages in pioneering research aimed at delivering transformative therapies to improve patient outcomes for individuals suffering from rare but severe neurological cancers. As a preclinical stage pharmaceutical company, CNS Pharmaceuticals represents a research-focused biotech enterprise working to advance treatment options in an area of significant unmet medical need.
CEO Mr. Rami Levin M.B.A. · 8 employees · United States · https://cnspharma.com